Literature DB >> 9694916

Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.

E H Ohlstein1, P Nambi, D W Hay, M Gellai, D P Brooks, J Luengo, J N Xiang, J D Elliott.   

Abstract

The present study describes the pharmacological profile of ((E)-alpha-[[1-butyl-5-[2-[(2-carboxyphenyl)methoxy]-4-methoxy-phenyl ]-1H-pyrazol-4-yl]methlene]-6-methoxy-1,3-benzodioxole-5-propanoic acid) (SB 234551), a high-affinity, nonpeptide endothelin type A (ETA)-selective receptor antagonist. In human cloned ETA and endothelin type B (ETB) receptors, SB 234551 produced a concentration-dependent displacement of [125I]-endothelin-1 with Ki values of 0.13 and 500 nM, respectively. SB 234551 elicited concentration-dependent, rightward competitive shifts in the endothelin-1 concentration-response curves in isolated rat aorta and isolated human pulmonary artery (ETA receptor-mediated vascular contraction) with Kb values of 1.9 and 1.0 nM, respectively. SB 234551 antagonized ETB receptor-mediated vasoconstriction in the isolated rabbit pulmonary artery, as demonstrated by concentration-dependent, rightward shifts in the sarafotoxin S6c concentration-response curves (Kb = 555 nM). SB 234551 produced weak functional inhibition of sarafotoxin S6c-mediated endothelium-dependent relaxation (IC50 = 7 microM). SB 234551 (10 microM) had no significant effect against contraction produced by several other vasoactive agents and did not significantly influence radioligand binding to a number of diverse receptors. SB 234551 (0. 1-1.0 mg/kg i.v.) dose-dependently inhibited the pressor response to exogenous endothelin-1 in conscious rats. In vivo pharmacokinetic analysis in the rat demonstrated that SB 234551 was rapidly absorbed from the GI tract with a bioavailability of 30%. SB 234551 had a plasma half-life of 125 min and a systemic clearance of 25.0 ml/min/kg. The present study demonstrates that SB 234551 is an antagonist with high affinity for the ETA receptor, while sparing the ETB receptor. SB 234551 is a new pharmacological tool that should assist in the elucidation of the role of endothelin in pathophysiology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694916

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive ((mRen-2)27) rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Differential modulation of endothelin ligand-induced contraction in isolated tracheae from endothelin B (ET(B)) receptor knockout mice.

Authors:  D W Hay; S A Douglas; Z Ao; R M Moesker; G J Self; P J Rigby; M A Luttmann; R G Goldie
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Effects of the novel selective endothelin ET(A) receptor antagonist, SB 234551, on the cardiovascular responses to endotoxaemia in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 4.  Endothelin in cardiovascular control: the role of endothelin antagonists.

Authors:  R R Wenzel; P Czyborra; T Lüscher; T Philipp
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

5.  Trigeminal nerve ganglion stimulation-induced neurovascular reflexes in the anaesthetized cat: role of endothelin(B) receptors in carotid vasodilatation.

Authors:  P Raval; S Bingham; N Aiyar; J D Elliott; A J Hunter; E H Ohlstein; A A Parsons
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

6.  Stimuli of sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ET(A)-receptor complexes.

Authors:  Merlijn J P M T Meens; Matthijs G Compeer; Tilman M Hackeng; Marc A van Zandvoort; Ben J A Janssen; Jo G R De Mey
Journal:  PLoS One       Date:  2010-06-01       Impact factor: 3.240

7.  Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.

Authors:  William Cruz-Muñoz; Maria L Jaramillo; Shan Man; Ping Xu; Myriam Banville; Catherine Collins; Andre Nantel; Giulio Francia; Sherif S Morgan; Lee D Cranmer; Maureen D O'Connor-McCourt; Robert S Kerbel
Journal:  Cancer Res       Date:  2012-08-03       Impact factor: 12.701

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.